Researchers sought to determine if adding cabazitaxel to a regimen of androgen deprivation therapy plus radiotherapy improved clinical progression free survival in very high risk prostate cancer.
Continued strong financial results and cash generation, achieving all 2025 guidance metrics Full year earnings growth; GAAP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results